Vivesto
ISIN: SE0000722365 | Ticker: VIVE | LEI: 5493003TZPR4B7QO9L49
Country: Sweden
Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.
Year founded1988
Served areaWorldwide
HeadquartersVallongatan 1, 75216 Uppsala – Sweden
| Line item in (sek) | 01.05.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 863,542,000.00 | 594,308,000.00 | 355,876,000.00 |
| Noncurrent Assets | N/A | 447,462,000.00 | 457,813,000.00 | 205,558,000.00 |
| Property Plant And Equipment | N/A | 17,630,000.00 | 17,108,000.00 | 12,964,000.00 |
| Intangible Assets Under Development | N/A | 420,334,000.00 | 400,799,000.00 | 158,408,000.00 |
| Other Intangible Assets | N/A | 9,197,000.00 | 39,605,000.00 | 33,885,000.00 |
| Current Assets | N/A | 416,079,000.00 | 136,495,000.00 | 150,318,000.00 |
| Inventories | N/A | 51,496,000.00 | 9,897,000.00 | 0.00 |
| Current Trade Receivables | N/A | 1,489,000.00 | 10,101,000.00 | 1,259,000.00 |
| Other Current Receivables | N/A | 43,063,000.00 | 8,680,000.00 | 2,328,000.00 |
| Cash and cash equivalents | 201,018,000.00 | 40,128,000.00 | 7,912,000.00 | 9,467,000.00 |
| Current Investments | N/A | 247,277,000.00 | 89,357,000.00 | 133,046,000.00 |
| Equity And Liabilities | N/A | 863,542,000.00 | 594,308,000.00 | 355,876,000.00 |
| Equity | 819,389,000.00 | 680,197,000.00 | 549,713,000.00 | 325,424,000.00 |
| Issued Capital | N/A | 44,837,000.00 | 44,837,000.00 | 53,804,000.00 |
| Retained Earnings | N/A | -1,268,657,000.00 | -1,401,379,000.00 | -1,758,098,000.00 |
| Other Reserves | N/A | -743,000.00 | 427,000.00 | 390,000.00 |
| Additional Paidin Capital | N/A | 1,904,760,000.00 | 1,905,828,000.00 | 2,029,327,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 680,197,000.00 | 549,713,000.00 | 325,424,000.00 |
| Noncontrolling Interests | N/A | 0.00 | 0.00 | 0.00 |
| Liabilities | N/A | 183,345,000.00 | 44,595,000.00 | 30,452,000.00 |
| Noncurrent Liabilities | N/A | 6,545,000.00 | 5,141,000.00 | 5,181,000.00 |
| Current Liabilities | N/A | 176,800,000.00 | 39,454,000.00 | 25,272,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 10,678,000.00 | 13,590,000.00 | 7,000,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 17,270,000.00 | 12,956,000.00 |
| Other Current Payables | N/A | 4,660,000.00 | 3,307,000.00 | 2,329,000.00 |
| Line item in (sek) | 01.05.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 482,000.00 | 26,192,000.00 | 1,015,000.00 |
| Other Income | 2,489,000.00 | 42,481,000.00 | 3,962,000.00 |
| Changes In Inventories Of Finished Goods And Work In Progress | -21,672,000.00 | 42,258,000.00 | 10,246,000.00 |
| Other Work Performed By Entity And Capitalised | 0.00 | 0.00 | N/A |
| Raw Materials And Consumables Used | 4,062,000.00 | 1,864,000.00 | 1,425,000.00 |
| Employee Benefits Expense | 45,519,000.00 | 44,883,000.00 | 33,829,000.00 |
| Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 28,930,000.00 | 28,877,000.00 | 256,155,000.00 |
| Other Expense By Nature | 77,627,000.00 | 79,438,000.00 | 58,371,000.00 |
| Profit Loss From Operating Activities | -131,493,000.00 | -128,647,000.00 | -355,049,000.00 |
| Finance Income | 4,138,000.00 | 2,460,000.00 | 1,460,000.00 |
| Finance Costs | 12,915,000.00 | 6,534,000.00 | 3,130,000.00 |
| Profit Loss Before Tax | -140,270,000.00 | -132,722,000.00 | -356,719,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -140,270,000.00 | -132,722,000.00 | -356,719,000.00 |
| Profit Loss Attributable To Owners Of Parent | -140,270,000.00 | -132,722,000.00 | -356,719,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 | 0.00 |
| Line item in (sek) | 01.05.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -140,270,000.00 | -132,722,000.00 | -356,719,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -22,658,000.00 | 41,599,000.00 | 9,897,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | -6,563,000.00 | 57,462,000.00 | 12,682,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | -11,846,000.00 | 2,874,000.00 | -6,590,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | N/A | 8,680,000.00 | -138,566,000.00 | -5,958,000.00 |
| Other Adjustments For Noncash Items | N/A | 29,413,000.00 | 28,877,000.00 | 256,155,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 680,000.00 | 552,000.00 | 495,000.00 |
| Interest Received Classified As Operating Activities | N/A | 3,000.00 | 0.00 | N/A |
| Cash Flows From Used In Operating Activities | N/A | -136,575,000.00 | -145,565,000.00 | -80,517,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 4,366,000.00 | 1,113,000.00 | 277,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 0.00 | 33,236,000.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | -14,366,000.00 | 118,651,000.00 | -45,277,000.00 |
| Proceeds From Issuing Shares | N/A | N/A | 0.00 | 150,652,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 4,010,000.00 | 5,809,000.00 | 5,495,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -4,010,000.00 | -5,809,000.00 | 128,763,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -154,952,000.00 | -32,723,000.00 | 2,969,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -5,938,000.00 | 507,000.00 | -1,414,000.00 |
| Cash and cash equivalents | 201,018,000.00 | 40,128,000.00 | 7,912,000.00 | 9,467,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 19.08.21 | Anders Härfstrand | Other | Buy | SEK 53,132.58 |
| 16.07.21 | Peter Zonabend | Other | Buy | SEK 302,623.60 |
| 14.07.21 | Fredrik Järrsten | Other | Buy | SEK 58,200.00 |
| 13.07.21 | Francois-Regis Martelet | Other | Buy | SEK 121,370.00 |
| 08.07.21 | Birgit Agneta Stattin Norinder | Other | Buy | SEK 104,480.00 |
| 06.07.21 | Anders Härfstrand | Other | Buy | SEK 285,653.00 |
| 13.10.20 | Francois-Regis Martelet | Other | Buy | SEK 85,000.00 |
| 12.10.20 | Anders Härfstrand | Other | Buy | SEK 130,800.00 |
| 18.06.20 | Sven Rohmann | Other | Sell | SEK 620,638.00 |
| 18.06.20 | Sven Rohmann | Other | Sell | SEK 504,702.80 |
SE0000722365
LEI5493003TZPR4B7QO9L49
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.